Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression

D. L. Stirewalt, F. R. Appelbaum, C. L. Willman, R. A. Zager, D. E. Banker

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression'. Together they form a unique fingerprint.

Medicine & Life Sciences